EFFECT OF PUTA IN ABHRAKA MARANA W.S.R. TO MADHUMEHA ( TYPE-2 DM )
试验速览
- 阶段
- 1/2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- It is expected that the trial drugs will exert a significant action over classical symptomatology of Madhumeha (Prabhutamutrata, Avilamutrata)
研究概览
简要总结
Almost all Rasavarga Dravya are used therapeutically essentially after Shodhana and Marana. Abhraka is one among the drugs which are said to use after proper process of *Marana.*Abhraka is among Rasavarga dravya for whome maximum number of repetitive cycles of Puta that is 1000 are mentioned in ancient classics on Rasa Shastra. Although Bhasma of Abhraka can be prepared with single Puta, yet 1000 repetitive cycles of Puta are also mentioned for its marana.
Abhraka is said to posses Pramehahara property and said to be used in all diseases. It is among few Rasavarga dravya which predominantly have Yogavahi and Rasayana property.In Prameha, 10 dushya gets affected hence drug posseing Rasayana property along with Pramehahara effect would be drug of choice, which Abhraka Bhasma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 30.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •Both the sexes having Age between 30 years to 60 years Patients having classical symptomatology of Madhumeha (Prabhutamutrata, Avilamutrata etc) Symptoms of Diabetes (Polyuria, Polydipsia, Polyphagia and Weight loss) Patients having Blood sugar Fasting Blood Sugar ≥ 126 mg/dl Post Prandial Blood Sugar ≥ 200 mg/dl.
排除标准
- •Age below 30 and above 60 years.
- •Patients of Diabetes Mellitus receiving Insulin.
- •Malignant and accelerated Hypertension.
- •Patients having chronic complications of Diabetes Mellitus a.Microvascular: Retinopathy, Neuropathy, & Nephropathy.
- •b.Macrovascular: Coronary artery disease, Peripheral vascular disease & Cerebro-vascular disease.
- •c.Other chronic debilitating diseases like STD etc.
- •5.Pregnant women.
- •6.Lactating mothers.
- •7.Secondary Diabetes mellitus.
- •8.Patients of any other severe illness.
- •9.Severe Iron deficiency anemia with Hb% less than 7mg/dl.
结局指标
主要结局
It is expected that the trial drugs will exert a significant action over classical symptomatology of Madhumeha (Prabhutamutrata, Avilamutrata)
时间窗: up to 8 weeks
次要结局
- It will help to live diabetic patient more healthy and without complications(Up to 4 weeks)